When an mTOR inhibitor, everolimus, was given to TSC patients with AMLs 3 cm or larger, 42% of patients had a reduction greater than 50% in volume, with 92% progression-free survival at 12 months. This evidence concerns the gene MTOR and tuberous sclerosis.